

INIM0031: Neoplasia and its Treatment

[View Online](#)

Ajila, V. et al. (2015) 'Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck', *Journal of Sexually Transmitted Diseases*, 2015, pp. 1–5. Available at: <https://doi.org/10.1155/2015/791024>.

Barrett, D.M., Grupp, S.A. and June, C.H. (2015) 'Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street', *The Journal of Immunology*, 195(3), pp. 755–761. Available at: <https://doi.org/10.4049/jimmunol.1500751>.

Ecker, D.M., Jones, S.D. and Levine, H.L. (2015) 'The therapeutic monoclonal antibody market', *mAbs*, 7(1), pp. 9–14. Available at: <https://doi.org/10.4161/19420862.2015.989042>.

Gill, S. and June, C.H. (2015) 'Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies', *Immunological Reviews*, 263(1), pp. 68–89. Available at: <https://doi.org/10.1111/imr.12243>.

Grupp, S.A. et al. (2013) 'Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia', *New England Journal of Medicine*, 368(16), pp. 1509–1518. Available at: <https://doi.org/10.1056/NEJMoa1215134>.

Hanahan, D. and Weinberg, R.A. (2000) 'The Hallmarks of Cancer', *Cell*, 100(1), pp. 57–70. Available at: [https://doi.org/10.1016/S0092-8674\(00\)81683-9](https://doi.org/10.1016/S0092-8674(00)81683-9).

zur Hausen, H. (2009) 'Papillomaviruses in the causation of human cancers — a brief historical account', *Virology*, 384(2), pp. 260–265. Available at: <https://doi.org/10.1016/j.virol.2008.11.046>.

Hodi, F.S. et al. (2010) 'Improved Survival with Ipilimumab in Patients with Metastatic Melanoma', *New England Journal of Medicine*, 363(8), pp. 711–723. Available at: <https://doi.org/10.1056/NEJMoa1003466>.

Jeggo, P.A., Pearl, L.H. and Carr, A.M. (2015) 'DNA repair, genome stability and cancer: a historical perspective', *Nature Reviews Cancer*, 16(1), pp. 35–42. Available at: <https://doi.org/10.1038/nrc.2015.4>.

Kaufman, H.L., Kohlhapp, F.J. and Zloza, A. (2015) 'Oncolytic viruses: a new class of immunotherapy drugs', *Nature Reviews Drug Discovery*, 14(9), pp. 642–662. Available at: <https://doi.org/10.1038/nrd4663>.

Klebanoff, C.A., Rosenberg, S.A. and Restifo, N.P. (2016) 'Prospects for gene-engineered T cell immunotherapy for solid cancers', *Nature Medicine*, 22(1), pp. 26–36. Available at:

<https://doi.org/10.1038/nm.4015>.

Koebel, C.M. et al. (2007) 'Adaptive immunity maintains occult cancer in an equilibrium state', *Nature*, 450(7171), pp. 903–907. Available at: <https://doi.org/10.1038/nature06309>.

Larson, C. et al. (2015) 'Going viral: a review of replication-selective oncolytic adenoviruses', *Oncotarget*, 6(24). Available at: <https://doi.org/10.18632/oncotarget.5116>.
Lazebnik, Y. (2010) 'What are the hallmarks of cancer?', *Nature Reviews Cancer*, 10(4), pp. 232–233. Available at: <https://doi.org/10.1038/nrc2827>.

Lingyun Geng (2015) 'Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments', *International Journal of Clinical and Experimental Medicine*, 8(9). Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658837/>.

de Martel, C. et al. (2012) 'Global burden of cancers attributable to infections in 2008: a review and synthetic analysis', *The Lancet Oncology*, 13(6), pp. 607–615. Available at: [https://doi.org/10.1016/S1470-2045\(12\)70137-7](https://doi.org/10.1016/S1470-2045(12)70137-7).

Matsuoka, M. and Jeang, K.-T. (2011) 'Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy', *Oncogene*, 30(12), pp. 1379–1389. Available at: <https://doi.org/10.1038/onc.2010.537>.

Morris, E.C. and Stauss, H.J. (2016) 'Optimizing T-cell receptor gene therapy for hematologic malignancies', *Blood*, 127(26), pp. 3305–3311. Available at: <https://doi.org/10.1182/blood-2015-11-629071>.

Palucka, K. and Banchereau, J. (2012) 'Cancer immunotherapy via dendritic cells', *Nature Reviews Cancer*, 12(4), pp. 265–277. Available at: <https://doi.org/10.1038/nrc3258>.

Pierangeli, A., Antonelli, G. and Gentile, G. (2015) 'Immunodeficiency-associated viral oncogenesis', *Clinical Microbiology and Infection*, 21(11), pp. 975–983. Available at: <https://doi.org/10.1016/j.cmi.2015.07.009>.

Reichert, J.M. (2012) 'Marketed therapeutic antibodies compendium', *mAbs*, 4(3), pp. 413–415. Available at: <https://doi.org/10.4161/mabs.19931>.

Reichert, J.M. (2016) 'Antibodies to watch in 2016', *mAbs*, 8(2), pp. 197–204. Available at: <https://doi.org/10.1080/19420862.2015.1125583>.

Reichert, J.M. (2017) 'Antibodies to watch in 2017', *mAbs*, 9(2), pp. 167–181. Available at: <https://doi.org/10.1080/19420862.2016.1269580>.

Restifo, N.P., Dudley, M.E. and Rosenberg, S.A. (2012) 'Adoptive immunotherapy for cancer: harnessing the T cell response', *Nature Reviews Immunology*, 12(4), pp. 269–281. Available at: <https://doi.org/10.1038/nri3191>.

Robbins, P.F. et al. (2011) 'Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1', *Journal of Clinical Oncology*, 29(7), pp. 917–924. Available at: <https://doi.org/10.1200/JCO.2010.32.2537>.

Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth (2011) 'Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion', *Science*, 331(6024), pp. 1565–1570. Available at: http://www.jstor.org/stable/29783923?seq=1#page_scan_tab_contents.

Roos, W.P., Thomas, A.D. and Kaina, B. (2015) 'DNA damage and the balance between survival and death in cancer biology', *Nature Reviews Cancer*, 16(1), pp. 20–33. Available at: <https://doi.org/10.1038/nrc.2015.2>.

Russell, S.J., Peng, K.-W. and Bell, J.C. (2012) 'Oncolytic virotherapy', *Nature Biotechnology*, 30(7), pp. 658–670. Available at: <https://doi.org/10.1038/nbt.2287>.

Schinzari, V., Barnaba, V. and Piconese, S. (2015) 'Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors', *Clinical Microbiology and Infection*, 21(11), pp. 969–974. Available at: <https://doi.org/10.1016/j.cmi.2015.06.026>.

Schumacher, T.N. and Schreiber, R.D. (2015) 'Neoantigens in cancer immunotherapy', *Science*, 348(6230), pp. 69–74. Available at: <https://doi.org/10.1126/science.aaa4971>.

Shankaran, V. et al. (2001) 'IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity', *Nature*, 410(6832), pp. 1107–1111. Available at: <https://doi.org/10.1038/35074122>.

Spurgeon, M.E. and Lambert, P.F. (2013) 'Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential', *Virology*, 435(1), pp. 118–130. Available at: <https://doi.org/10.1016/j.virol.2012.09.029>.

Topalian, S.L. et al. (2012) 'Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer', *New England Journal of Medicine*, 366(26), pp. 2443–2454. Available at: <https://doi.org/10.1056/NEJMoa1200690>.

Varghese, S. and Rabkin, S.D. (2002) 'Oncolytic herpes simplex virus vectors for cancer virotherapy', *Cancer Gene Therapy*, 9(12), pp. 967–978. Available at: <https://doi.org/10.1038/sj.cgt.7700537>.

Weinberg, R.A. (2014) *The biology of cancer*. 2nd ed. New York: Garland Science.

Weiss, R.A. and Vogt, P.K. (2011) '100 years of Rous sarcoma virus', *The Journal of Experimental Medicine*, 208(12), pp. 2351–2355. Available at: <https://doi.org/10.1084/jem.20112160>.

Wendzicki, J.A., Moore, P.S. and Chang, Y. (2015) 'Large T and small T antigens of Merkel cell polyomavirus', *Current Opinion in Virology*, 11, pp. 38–43. Available at: <https://doi.org/10.1016/j.coviro.2015.01.009>.